Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience.
Acute myeloid leukemia
Khorana score
Risk prediction
Thrombosis
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
04
2019
accepted:
27
05
2019
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Although patients with acute myeloid leukemia (AML) were shown to have an increased risk of thrombosis, no thrombosis risk assessment scoring system has been developed for AML patients. The Khorana Risk Score (KRS), which has been widely used for thrombosis risk assessment in the clinical setting, was developed on the basis of solid tumor data and has not been validated among AML patients. This study aims to validate the use of the KRS as a thrombosis risk-scoring system among patients with AML. Using data from H. Lee Moffitt Cancer Center and Research Institution's Total Cancer Care Research Study, we retrospectively identified patients who were histologically confirmed with AML from 2000 to 2018. Clinical and laboratory variables at the time of AML diagnosis were characterized and analyzed. The thrombotic event rate was estimated with the Kaplan-Meier method and compared using the log-rank test. A total of 867 AML patients were included in the analysis. The median age at AML diagnosis was 75 years (range, 51-96), and the majority were male (65%, Although there was an increased risk of thrombosis associated with a higher KRS among AML patients with a KRS of 1 to 3, the difference was not statistically significant. Furthermore, only a few patients were found to have a KRS > 3, and this was largely due to pancytopenia, which is commonly associated with AML. These results indicate the need for a better thrombotic risk-scoring system for AML patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although patients with acute myeloid leukemia (AML) were shown to have an increased risk of thrombosis, no thrombosis risk assessment scoring system has been developed for AML patients. The Khorana Risk Score (KRS), which has been widely used for thrombosis risk assessment in the clinical setting, was developed on the basis of solid tumor data and has not been validated among AML patients. This study aims to validate the use of the KRS as a thrombosis risk-scoring system among patients with AML.
METHODS
METHODS
Using data from H. Lee Moffitt Cancer Center and Research Institution's Total Cancer Care Research Study, we retrospectively identified patients who were histologically confirmed with AML from 2000 to 2018. Clinical and laboratory variables at the time of AML diagnosis were characterized and analyzed. The thrombotic event rate was estimated with the Kaplan-Meier method and compared using the log-rank test.
RESULTS
RESULTS
A total of 867 AML patients were included in the analysis. The median age at AML diagnosis was 75 years (range, 51-96), and the majority were male (65%,
CONCLUSIONS
CONCLUSIONS
Although there was an increased risk of thrombosis associated with a higher KRS among AML patients with a KRS of 1 to 3, the difference was not statistically significant. Furthermore, only a few patients were found to have a KRS > 3, and this was largely due to pancytopenia, which is commonly associated with AML. These results indicate the need for a better thrombotic risk-scoring system for AML patients.
Identifiants
pubmed: 31303864
doi: 10.1186/s12959-019-0202-z
pii: 202
pmc: PMC6604148
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Clin Invest. 1991 Mar;87(3):986-95
pubmed: 1705569
Blood. 2016 Oct 6;128(14):1854-1861
pubmed: 27354723
Thromb Res. 2017 Feb;150:30-32
pubmed: 28002757
J Thromb Haemost. 2018 Jul;16(7):1321-1326
pubmed: 29733498
J Pediatr Surg. 1992 May;27(5):665-7
pubmed: 1625146
Thromb Res. 2009;123 Suppl 4:S18-21
pubmed: 19303497
Clin Appl Thromb Hemost. 2018 Apr;24(3):471-476
pubmed: 28288526
Blood. 1988 Oct;72(4):1368-74
pubmed: 3139106
Thromb Res. 2018 Apr;164 Suppl 1:S70-S76
pubmed: 29395243
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Thromb Haemost. 2020 Feb;120(2):322-328
pubmed: 31893562
Expert Rev Anticancer Ther. 2018 Jun;18(6):567-578
pubmed: 29575945
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Blood. 2017 Jul 27;130(4):558
pubmed: 28751360
Curr Opin Oncol. 2017 Nov;29(6):448-454
pubmed: 28841588
Sci Rep. 2017 Apr 26;7(1):1167
pubmed: 28446766
Thromb Res. 2013 Apr;131(4):281-9
pubmed: 23266518
Br J Haematol. 1996 Aug;94(2):413-6
pubmed: 8759907
Thromb Haemost. 2015 Jan;113(1):201-8
pubmed: 25339605
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
Vasc Med. 2007 Aug;12(3):199-202
pubmed: 17848476
Blood. 2016 Oct 6;128(14):1784-1785
pubmed: 28832329
J Thromb Haemost. 2013 Jan;11(1):56-70
pubmed: 23217107
Rev Clin Exp Hematol. 2004 Jun 01;8(1):E4
pubmed: 16029970
Curr Opin Hematol. 2016 Mar;23(2):121-6
pubmed: 26760586
Indian J Hematol Blood Transfus. 2019 Oct;35(4):611-624
pubmed: 31741612
Med Oncol. 2017 Dec 4;35(1):5
pubmed: 29209847
Hematology Am Soc Hematol Educ Program. 2012;2012:74-5
pubmed: 23233563
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
J Clin Oncol. 2006 Jan 20;24(3):484-90
pubmed: 16421425
Platelets. 2016 Sep;27(6):497-504
pubmed: 27100842
Cancer Med. 2015 Jan;4(1):27-35
pubmed: 25487644
J Thromb Thrombolysis. 2018 Apr;45(3):377-385
pubmed: 29417408